GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

The global Healthcare Contract Manufacturing Market size is projected to be valued at USD 183.7 billion in 2023 and reach USD 347.5 billion by 2030, growing at a CAGR of 9.5% according to a new report ...

Journalists and news professionals across Canada today are launching an industry-wide mental health support program to combat stress, burnout and trauma exposure. Twenty volunteers were trained this ...

Depemokimab, GSK’s long-acting, anti-interleukin (IL)-5 monoclonal antibody (mAB), is currently under review as an add-on maintenance treatment for asthma in paediatric (≥12 years old ...

Two of the treatments that will be receiving plenty of attention in GSK’s presentations are mepolizumab and depemokimab, which are both monoclonal antibodies (mAbs) that target IL-5, a key cytokine or ...

GSK has taken steps to boost US manufacturing amid tariff threats ... in chronic obstructive pulmonary disorder (COPD), and its new asthma biologic depemokimab.

Daniel J. Jackson In the previous phase 3 SWIFT-1/2 studies, two doses of depemokimab (GSK) administered at week 0 and 26 in addition to standard of care reduced asthma exacerbations by ...

GSK. “Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress interleukin-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of ...

GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus placebo (both with standard of care [SOC]) in ...

LONDON (dpa-AFX) - GSK plc (GSK) has announced on Monday that the FDA has accepted its Biologics License Application (BLA) for depemokimab for regulatory review in two indications. The proposed ...